Meeting
2019 ASCO Annual Meeting
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
Authors
Amod Sarnaik
H. Lee Moffitt Cancer Center, Tampa, FL
Amod Sarnaik , Nikhil I. Khushalani , Jason Alan Chesney , Harriet M. Kluger , Brendan D. Curti , Karl D. Lewis , Sajeve Samuel Thomas , Eric D. Whitman , Omid Hamid , Jose Lutzky , Anna C. Pavlick , Jeffrey S. Weber , James M.G. Larkin , Debora Barton , Lotus Yung , Sam Suzuki , Maria Fardis , John M. Kirkwood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT02360579
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2518)
DOI
10.1200/JCO.2019.37.15_suppl.2518
Abstract #
2518
Poster Bd #
162
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
First Author: Amod Sarnaik
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2018 ASCO Annual Meeting
A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.
First Author: Amod Sarnaik
Poster
2018 ASCO Annual Meeting
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
First Author: Sylvia Mina Lee